Borage and fish oils lifelong supplementation decreases inflammation and improves bone health in a murine model of senile osteoporosis

Bone

Volumn 50, Issue 2, 2012, Pages 553-561

  Wauquier, Fabien ^a,b,c   Barquissau, Valentin ^a,b,d   Léotoing, Laurent ^a,b,c   Davicco, Marie Jeanne ^a,b,c   Lebecque, Patrice ^a,b,c   Mercier, Sylvie ^a,b,c   Philippe, Claire ^a,b,c   Miot Noirault, Elisabeth ^a,e   Chardigny, Jean Michel ^a,b,d   Morio, Béatrice ^a,b,d   Wittrant, Yohann ^a,b,c   Coxam, Véronique ^a,b,c  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b CRNH AUVERGNE   (France)

^c Equipe Alimentation Squelette et Métabolismes   (France)

^d Equipe ContrÔle de l'Homeostasie Lipido Energétique et Obésité   (France)

^e INSERM   (France)

Author keywords

Aging; Inflammation; Lipids; Nutrition; Osteoporosis; SAMP8

Indexed keywords

CALCITONIN RECEPTOR; CELL MARKER; FATTY ACID; FISH OIL; GAMMA LINOLENIC ACID; GELATINASE A; GELATINASE B; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TRANSCRIPTION FACTOR OSTERIX;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CELL; BONE GROWTH; BONE MINERALIZATION; BONE REMODELING; BORAGO; CLINICAL FEATURE; CONTROLLED STUDY; DIET SUPPLEMENTATION; INFLAMMATION; MOUSE; MUSCLE MASS; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; SENILE OSTEOPOROSIS; SUNFLOWER; THERAPY EFFECT; TREATMENT DURATION;

ADIPOSITY; ANIMALS; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; BORAGO; CALCIFICATION, PHYSIOLOGIC; DIETARY FATS; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; FISH OILS; HEALTH; HELIANTHUS; INFLAMMATION; MICE; MICE, MUTANT STRAINS; ORGAN SIZE; OSTEOPOROSIS; PLANT OILS;

EID: 84855900674     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.05.030     Document Type: Article

References (32)

1. Cooper C. Osteoporosis: disease severity and consequent fracture management. Osteoporos Int Jun 2010, (Suppl. 2):S425-S429.
2. Ozgocmen S., Kaya H., Fadillioglu E., Aydogan R., Yilmaz Z. Role of antioxidant systems, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis. Mol Cell Biochem Jan 2007, 295:45-52.
3. Mann V., Huber C., Kogianni G., Collins F., Noble B. The antioxidant effect of estrogen and selective estrogen receptor modulators in the inhibition of osteocyte apoptosis in vitro. Bone Mar 2007, 40:674-684.
4. Valverde P. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem 2008, 15:284-304.
5. Ono K., Kaneko H., Choudhary S., Pilbeam C.C., Lorenzo J.A., Akatsu T., et al. Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor. J Bone Miner Res Jan 2005, 20:23-29.
6. Tsutsumi R., Xie C., Wei X., Zhang M., Zhang X., Flick L.M., et al. PGE2 signaling through the EP4 receptor on fibroblasts upregulates RANKL and stimulates osteolysis. J Bone Miner Res Oct 2009, 24:1753-1762.
7. Laneuville O., Breuer D.K., Xu N., Huang Z.H., Gage D.A., Watson J.T., et al. Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)-octadecatrienoic acids from alpha-linolenic acid. J Biol Chem Aug 18 1995, 270:19330-19336.
8. Raisz L.G., Alander C.B., Simmons H.A. Effects of prostaglandin E3 and eicosapentaenoic acid on rat bone in organ culture. Prostaglandins May 1989, 37:615-625.
9. Corwin R.L. Effects of dietary fats on bone health in advanced age. Prostaglandins Leukot Essent Fatty Acids Jun 2003, 68:379-386.
10. Calder P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr Jun 2006, 83:1505S-1519S.
11. Derave W., Eijnde B.O., Ramaekers M., Hespel P. No effects of lifelong creatine supplementation on sarcopenia in senescence-accelerated mice (SAMP8). Am J Physiol Aug 2005, 289:E272-E277.
12. Lo W.C., Chiou J.F., Gelovani J.G., Cheong M.L., Lee C.M., Liu H.Y., et al. Transplantation of embryonic fibroblasts treated with platelet-rich plasma induces osteogenesis in SAMP8 mice monitored by molecular imaging. J Nucl Med May 2009, 50:765-773.
13. Kruger M.C., Coetzee M., Haag M., Weiler H. Long-chain polyunsaturated fatty acids: selected mechanisms of action on bone. Prog Lipid Res Oct 2010, 49:438-449.
14. Martinez-Ramirez M.J., Palma S., Martinez-Gonzalez M.A., Delgado-Martinez A.D., de la Fuente C., Delgado-Rodriguez M. Dietary fat intake and the risk of osteoporotic fractures in the elderly. Eur J Clin Nutr Sep 2007, 61:1114-1120.
15. Watkins B.A., Lippman H.E., Le Bouteiller L., Li Y., Seifert M.F. Bioactive fatty acids: role in bone biology and bone cell function. Prog Lipid Res Jan-Mar 2001, 40:125-148.
16. Felson D.T., Zhang Y., Hannan M.T., Anderson J.J. Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res 1993, 8:567-573.
17. Saller A., Maggi S., Romanato G., Tonin P., Crepaldi G. Diabetes and osteoporosis. Aging Clin Exp Res 2008, 20:280-289.
18. Reid I.R. Relationships among body mass, its components, and bone. Bone 2002, 31:547-555.
19. Hardy R., Cooper M.S. Bone loss in inflammatory disorders. J Endocrinol 2009, 201:309-320.
20. Mundy G.R. Osteoporosis and inflammation. Nutr Rev 2007, 65:S147-S151.
21. Bruunsgaard H., Pedersen M., Pedersen B.K. Aging and proinflammatory cytokines. Curr Opin Hematol 2001, 8:131-136.
22. Theoleyre S., Wittrant Y., Tat S.K., Fortun Y., Redini F., Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004, 15:457-475.
23. Wauquier F., Leotoing L., Coxam V., Guicheux J., Wittrant Y. Oxidative stress in bone remodelling and disease. Trends Mol Med 2009, 15:468-477.
24. Rahman M.M., Bhattacharya A., Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J Cell Physiol 2008, 214:201-209.
25. Poulsen R.C., Wolber F.M., Moughan P.J., Kruger M.C. Long chain polyunsaturated fatty acids alter membrane-bound RANK-L expression and osteoprotegerin secretion by MC3T3-E1 osteoblast-like cells. Prostaglandins Other Lipid Mediat 2008, 85:42-48.
26. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
27. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
28. Moerman E.J., Teng K., Lipschitz D.A., Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004, 3:379-389.
29. Lecka-Czernik B., Moerman E.J., Grant D.F., Lehmann J.M., Manolagas S.C., Jilka R.L. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002, 143:2376-2384.
30. Ali A.A., Weinstein R.S., Stewart S.A., Parfitt A.M., Manolagas S.C., Jilka R.L. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226-1235.
31. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406.
32. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Investig 2004, 113:846-855.